Related Experiment Video
Updated: May 31, 2026
14:57
Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
Ca2+ dysfunction in neurodegenerative disorders: Alzheimer's disease
Laura Fedrizzi1, Ernesto Carafoli
1Department of Biochemistry, University of Padova, Italy.
Biofactors (Oxford, England)
|June 24, 2011
Summary
Calcium (Ca2+) homeostasis dysregulation plays a key role in Alzheimer's disease (AD) onset and progression. This review explores the essential aspects of Ca2+
Area of Science:
- Neuroscience
- Neuropathology
- Molecular Biology
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder characterized by dementia.
- Key neuropathological hallmarks include amyloid plaques and neurofibrillary tangles.
- Despite extensive research, the precise mechanisms underlying AD pathogenesis remain incompletely understood.
Purpose of the Study:
- To review the critical role of calcium (Ca2+) homeostasis dysregulation in Alzheimer's disease.
- To discuss the essential aspects of Ca2+ dysregulation in AD onset and development.
Main Methods:
- Literature review of existing hypotheses on Alzheimer's disease pathogenesis.
- Focus on the amyloid cascade hypothesis and the Ca2+ hypothesis.
- Synthesis of information regarding Ca2+ homeostasis and neurodegeneration.
Main Results:
- Two major hypotheses for AD pathogenesis are the amyloid cascade and the Ca2+ hypothesis.
- The Ca2+ hypothesis links neurodegeneration to impaired Ca2+ homeostasis.
- Dysregulation of Ca2+ homeostasis is implicated in the initiation and advancement of AD.
Conclusions:
- Calcium (Ca2+) homeostasis is a significant factor in Alzheimer's disease.
- Further research into Ca2+ dysregulation may reveal novel therapeutic targets for AD.
- Understanding Ca2+'s role is crucial for unraveling AD's complex mechanisms.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...